Shi-fang Yang

A multicenter, open‐label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma

J. Hou, X. Ke, L. Qiu, 2014, American journal of hematology.

Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480

Tienian Zhu, Xiujun Liang, Ruijing Zhao, 2018, Medical science monitor : international medical journal of experimental and clinical research.

A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma

J. Hou, L. Qiu, Wenming Chen, 2017, American journal of clinical oncology.

Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma

J. Hou, L. Qiu, Wenming Chen, 2016, Chinese journal of cancer.

Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study

Yan Liu, Hua Jiang, B. Jiang, 2017, Cancer Chemotherapy and Pharmacology.

Transiently Elevated AST/LDH Are Associated with Clinical Response to Recombinant Circularly Permuted TRAIL (CPT) Plus Thalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma

J. Hou, X. Ke, L. Qiu, 2014 .

Phase Ib Study of Recombinant Circularly Permuted TRAIL (CPT) in Relapsed or Refractory multiple Myeloma Patients

J. Hou, X. Ke, L. Qiu, 2012 .

Circularly Permuted TRAIL (CPT) combined with Thalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma: An Open-Label, Multicenter Phase II Clinical Trial.

J. Hou, X. Ke, L. Qiu, 2012 .